This was the ADR's second consecutive day of losses.

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

(Reuters) -AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said Datroway has secured US Food & Drug Administration approval for use in adult patients with previously treated advanced ...

In all, their investment portfolio pulled in an estimated 54% return in 2024, more than double the S&P 500’s 25% gain — and ...

The UK's FTSE 100 saw its five-week winning streak halted, influenced by global tensions between Israel and Iran, and ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Metabolism and obesity are the focus of a major research initiative by the University of Gothenburg and AstraZeneca, with the ...

The AstraZeneca (LSE: AZN) share price slumped 5% when the market opened on Monday (12 May). Fellow UK pharma giant GSK dipped too, losing 3.5% in early trading. Both regained a bit, with AstraZeneca ...